Orasis Pharmaceuticals introduces starter packs of pilocarpine hydrochloride ophthalmic solution 0.4%

Orasis Pharmaceuticals announced the availability of Starter Packs of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% to “broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals.”¹

The topical ophthalmic solution is preservative-free and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort. According to the company, patients can enjoy the flexibility of using a single drop per eye for improved near vision for a specific occasion or activity, or up to 2 drops daily for an extended effect lasting up to 8 hours.

The product’s proprietary EyeQ Formulation is designed to maximize efficacy while minimizing side effects. This is achieved by balancing the lowest approved concentration of pilocarpine at a near-neutral pH for optimal bioavailability.

Qlosi first became available in the United States in April 2025² following its FDA approval in October 2023.³ The approval was based on the results from 2 pivotal phase 3 clinical trials, NEAR-1 and NEAR-2 (NCT04599933​ and NCT04599972), which evaluated its efficacy, safety, and tolerability in more than 600 adult patients with presbyopia.

Paul Karpecki, OD, FAAO, director of cornea and external disease, Kentucky Eye Institute, and associate professor, University of Pikeville, Kentucky College of Optometry, commented on Qlosi, saying, "Many patients are surprised to learn that presbyopia can be treated with an eye drop. Qlosi has transformed these conversations, offering a flexible, comfortable option to improve near vision in appropriate patients. The feedback from my patients who have tried Qlosi has been outstanding, and with the Starter Packs, I now have an easy way to get them started on a new way of managing their presbyopia."

Each starter pack will come with 10 vials, 2 daily doses for 5 days of treatment, along with a patient progress tracker and referral card that are shipped directly to the prescribing eye care professionals for patient distribution.

References:

1. Orasis Pharmaceuticals expands access to QLOSI™ with new starter packs for eye care professionals, bolstering commercial rollout. Published November 13, 2025. Accessed November 18, 2025. https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-expands-access-to-qlosi-with-new-starter-packs-for-eye-care-professionals-bolstering-commerical-rollout-302613523.html

2. Stevenson S. Orasis Pharmaceuticals’ prescription pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi) for presbyopia available in the US. Published April 7, 2025. Accessed November 18, 2025. https://www.ophthalmologytimes.com/view/orasis-pharmaceuticals-prescription-pilocarpine-hydrochloride-ophthalmic-solution-0-4-qlosi-for-presbyopia-available-in-the-us

3. Hutton D. FDA approves pilocarpine hydrochloride ophthalmic solution for treatment of presbyopia. Published October 18, 2023. Accessed November 18, 2025. https://www.ophthalmologytimes.com/view/fda-approves-pilocarpine-hydrochloride-ophthalmic-solution-for-treatment-of-presbyopia